Literature DB >> 26343030

Quality of Life Outcomes for Bladder Cancer Patients Undergoing Bladder Preservation with Radiotherapy.

Michael A Feuerstein1, Anuj Goenka.   

Abstract

For patients with muscle-invasive bladder cancer, the decision to undergo radical cystectomy or bladder preservation treatment must incorporate survival differences, toxicity, and quality of life. Our objective was to review patient-reported outcomes for bladder preservation treatment with a focus on patients eligible for radical cystectomy, for whom a comparison of patient-reported outcomes is most relevant. Peer-reviewed, English-language manuscripts in MEDLINE and PubMed databases were examined from 1996 through 2014. Subject headings included quality of life, bladder cancer, bladder sparing, bladder preservation, radiation, and radiotherapy. Prospective and retrospective studies of patient-reported outcomes in patients undergoing bladder preservation with radiotherapy for muscle-invasive bladder cancer were included. Two prospective studies and four retrospective studies were identified. Several weaknesses from these studies were identified including small sample sizes, variable time points of assessment, variation in treatment regimens, and failure to use validated or condition-specific questionnaires. From the available data, bladder preservation appears to result to similar or better general quality of life compared to radical cystectomy with satisfactory urinary and sexual function reported in most series. In general, bladder preservation resulted in more gastrointestinal symptoms than radical cystectomy. This is one of the first reviews on the subject of patient-reported outcomes for bladder preservation in muscle-invasive bladder cancer. Although the data are limited, this review may provide a framework for developing well-designed, prospective comparisons of treatment for this patient cohort.

Entities:  

Mesh:

Year:  2015        PMID: 26343030     DOI: 10.1007/s11934-015-0547-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  16 in total

1.  Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence?

Authors:  Claus Rödel; Christian Weiss
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.

Authors:  Melanie Calvert; Jane Blazeby; Douglas G Altman; Dennis A Revicki; David Moher; Michael D Brundage
Journal:  JAMA       Date:  2013-02-27       Impact factor: 56.272

3.  Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire.

Authors:  O Caffo; G Fellin; U Graffer; L Luciani
Journal:  Cancer       Date:  1996-09-01       Impact factor: 6.860

Review 4.  Quality of life aspects of bladder cancer: a review of the literature.

Authors:  M F Botteman; C L Pashos; R S Hauser; B L Laskin; A Redaelli
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

5.  Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.

Authors:  Joseph M Herman; David C Smith; James Montie; James A Hayman; Molly A Sullivan; Elizabeth Kent; Kent A Griffith; Peggy Esper; Howard M Sandler
Journal:  Urology       Date:  2004-07       Impact factor: 2.649

Review 6.  Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology.

Authors:  Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Donald S Kaufman; Michael P Hagan; Niall M Heney; Howard M Sandler
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

8.  Assessing the value of patient-generated data to comparative effectiveness research.

Authors:  Lynn Howie; Bradford Hirsch; Tracie Locklear; Amy P Abernethy
Journal:  Health Aff (Millwood)       Date:  2014-07       Impact factor: 6.301

9.  The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.

Authors:  Jimmi Søndergaard; Morten Høyer; Jørgen B Petersen; Pauliina Wright; Cai Grau; Ludvig Paul Muren
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

10.  A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy.

Authors:  John C Roeske; Dacian Bonta; Loren K Mell; Anthony E Lujan; Arno J Mundt
Journal:  Radiother Oncol       Date:  2003-11       Impact factor: 6.280

View more
  10 in total

1.  Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Authors:  Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2019-01-31       Impact factor: 1.862

2.  Gastrointestinal consequences of cancer treatment: evaluation of 10 years' experience at a tertiary UK centre.

Authors:  Radha Gadhok; Emma Paulon; Chehkuan Tai; Tomisin Olushola; John Barragry; Farooq Rahman; Simona Di Caro; Shameer Mehta
Journal:  Frontline Gastroenterol       Date:  2020-08-11

Review 3.  SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Authors:  Jeffrey J Leow; Jens Bedke; Karim Chamie; Justin W Collins; Siamak Daneshmand; Petros Grivas; Axel Heidenreich; Edward M Messing; Trevor J Royce; Alexander I Sankin; Mark P Schoenberg; William U Shipley; Arnauld Villers; Jason A Efstathiou; Joaquim Bellmunt; Arnulf Stenzl
Journal:  World J Urol       Date:  2019-01-25       Impact factor: 4.226

4.  PPM-18, an Analog of Vitamin K, Induces Autophagy and Apoptosis in Bladder Cancer Cells Through ROS and AMPK Signaling Pathways.

Authors:  Huiai Lu; Chunlei Mei; Luhao Yang; Junyan Zheng; Junwei Tong; Fengsen Duan; Huageng Liang; Ling Hong
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

5.  Hedyotis diffusa plus Scutellaria barbata Induce Bladder Cancer Cell Apoptosis by Inhibiting Akt Signaling Pathway through Downregulating miR-155 Expression.

Authors:  Li-Tao Pan; Yip Sheung; Wen-Peng Guo; Zhi-Bin Rong; Zhi-Ming Cai
Journal:  Evid Based Complement Alternat Med       Date:  2016-02-17       Impact factor: 2.629

6.  How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial.

Authors:  Wojciech Krajewski; Katarzyna Kościelska-Kasprzak; Joanna Rymaszewska; Romuald Zdrojowy
Journal:  Qual Life Res       Date:  2017-01-03       Impact factor: 4.147

7.  Assessment of Pain Management, Acceptance of Illness, and Adjustment to Life with Cancer in Patients with Nonmuscle Invasive Bladder Cancer.

Authors:  Wojciech Krajewski; Małgorzata Mazur; Adrian Poterek; Agata Pastuszak; Urszula Halska; Andrzej Tukiendorf; Joanna Rymaszewska; Romuald Zdrojowy
Journal:  Biomed Res Int       Date:  2018-10-22       Impact factor: 3.411

8.  Clinical development of new drug-radiotherapy combinations.

Authors:  Ricky A Sharma; Ruth Plummer; Julie K Stock; Tessa A Greenhalgh; Ozlem Ataman; Stephen Kelly; Robert Clay; Richard A Adams; Richard D Baird; Lucinda Billingham; Sarah R Brown; Sean Buckland; Helen Bulbeck; Anthony J Chalmers; Glen Clack; Aaron N Cranston; Lars Damstrup; Roberta Ferraldeschi; Martin D Forster; Julian Golec; Russell M Hagan; Emma Hall; Axel-R Hanauske; Kevin J Harrington; Tom Haswell; Maria A Hawkins; Tim Illidge; Hazel Jones; Andrew S Kennedy; Fiona McDonald; Thorsten Melcher; James P B O'Connor; John R Pollard; Mark P Saunders; David Sebag-Montefiore; Melanie Smitt; John Staffurth; Ian J Stratford; Stephen R Wedge
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

9.  Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways.

Authors:  Fengsen Duan; Yuejin Yu; Rijian Guan; Zhiliang Xu; Huageng Liang; Ling Hong
Journal:  PLoS One       Date:  2016-08-29       Impact factor: 3.240

10.  Capsaicin Suppresses Cell Proliferation, Induces Cell Cycle Arrest and ROS Production in Bladder Cancer Cells through FOXO3a-Mediated Pathways.

Authors:  Kaiyu Qian; Gang Wang; Rui Cao; Tao Liu; Guofeng Qian; Xinyuan Guan; Zhongqiang Guo; Yu Xiao; Xinghuan Wang
Journal:  Molecules       Date:  2016-10-21       Impact factor: 4.927

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.